Northern Financial Advisors Inc Sells 563 Shares of Pfizer Inc. $PFE

Northern Financial Advisors Inc reduced its position in Pfizer Inc. (NYSE:PFE) by 6.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,857 shares of the biopharmaceutical company’s stock after selling 563 shares during the quarter. Northern Financial Advisors Inc’s holdings in Pfizer were worth $215,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter worth about $27,000. North Capital Inc. bought a new position in Pfizer during the 1st quarter worth about $28,000. Bayforest Capital Ltd bought a new position in Pfizer during the 1st quarter worth about $28,000. Horizon Financial Services LLC bought a new position in Pfizer during the 1st quarter worth about $35,000. Finally, WPG Advisers LLC bought a new position in Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PFE shares. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.41.

Pfizer Trading Down 0.6%

Pfizer stock opened at $26.27 on Wednesday. The stock has a 50-day moving average of $24.76 and a two-hundred day moving average of $24.14. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The stock has a market cap of $149.36 billion, a PE ratio of 13.97, a price-to-earnings-growth ratio of 0.86 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period last year, the business posted $0.60 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.